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Available online 10 November 2015The transcription factor ERG is known to have divergent roles. On one hand, it acts as differentiation factor of
endothelial cells. On the other hand, it has pathological roles in various cancers. Genomic analyses of the ERG
gene show that it gives rise to several isoforms. However, functional differences between these isoforms,
representing potential reasons for distinct effects in diverse cell types have not been addressed in detail so far.
We set out to investigate the major protein isoforms and found that ERG8 contains a unique C-terminus. This
isoform,when expressed asGFP-fusion protein, localizedmainly to the cytosol,whereas the othermajor isoforms
(ERG1-4) were predominantly nuclear. Using site directed mutagenesis and laser scanning microscopy of live
cells, we could identify nuclear localization (NLS) and nuclear export sequences (NES). These analyses indicated
that ERG8 lacks a classical NLS and the DNA-binding domain, but holds an additional NESwithin its distinctive C-
terminus. All the tested isoforms were shuttling between nucleus and cytosol and showed a high degree of mo-
bility. ERG's 1 to 4 were transcriptionally active on ERG-promoter elementswhereas ERG8was inactive, which is
in line with the absence of a DNA-binding domain. Fluorescence resonance energy transfer (FRET) microscopy
revealed that ERG8 can bind to the transcriptionally active ERG's. Knockdown of ERG8 in endothelial cells
resulted in upregulation of endogenous ERG-transcriptional activity implying ERG8 as an inhibitor of the active
ERG isoforms. Quantitative PCR revealed a different ratio of active ERG's to ERG8 in cancer- versus non-
transformed cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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ERG (ETS-related gene) is a member of the ETS-family of transcrip-
tion factors, which are characterized by a helix–turn–helix DNA binding
domain, and recognizes a highly conserved DNA binding sequence of
purine rich nucleotides GGAA/T [1]. When ﬁrst reported in 1987, ERG
was shown to have two variants [2]. This number was signiﬁcantly in-
creased later, when Owczarek et al., analyzed the genomic structure of
ERG on chromosome 21 in more detail using improved detection
methods, which led to the notion that ERG has at least 17 exons and
16 introns resulting in about 9 isoforms, which are the consequence of
alternative splicing [3]. Very recently an even more elaborate analysiscalization signal; NES, nuclear
bleaching; FRET, ﬂuorescence
d Thrombosis Research, Center
ustria, Schwarzspanierstr, 17,
1 40160 931101.
J.A. Schmid).
. This is an open access article underof the ERG variants has been published [4], which considers three alter-
native promoters, two splice sites, three separate polyadenylation sites
and a variety of different translation start sites resulting in about 30 pos-
sible ERG variants, of which only a subset is usually expressed on the
protein level. This latter analysis is the most elaborate and detailed de-
scription of ERG-isoforms. We set out to analyze ﬁve of the major ERG
isoforms as speciﬁed in Fig. 2A including ERG8,whichdiffers signiﬁcant-
ly from the other isoforms since it is lacking the DNA binding domain
and has a very distinct and unique C-terminus.
Despite the fact that the ERG gene is expressed in distinct isoforms
with potentially different functions, ERG is considered in most reports
as a single entity. ERG is physiologically highly expressed in the endo-
thelium where it is involved in vasculogenesis [5], angiogenesis [6]
and overall cell maintenance [7]. The expression of several endothelial
cell speciﬁc genes is under the control of ERG such as VE-cadherin [8],
endoglin [9] and Van-Willebrand factor [10]. Moreover it has also
been proposed that ERG regulates endothelial cell barrier functions
and that it suppresses inﬂammation by regulating the expression of
Claudin-5 [11], ICAM-1 [12] and IL-8 [13]. This anti-inﬂammatory effect
was reported to correlatewith a reduced serine-536 phosphorylation ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lial and hematopoietic cells, it is also pathologically expressed in about
50% of prostate cancer patients due to a fusion of the ERG gene with a
prostate-speciﬁc promoter [14]. Furthermore, disease related expres-
sion of ERG or ERG-fusion genes is observed in certain types of leukemia
[15] and in Ewing sarcoma [16].
In contrast to the inﬂammation dampening effect of ERG in endothe-
lial cells, it was reported to act as a pro-inﬂammatorymediator in pros-
tate cancer cells, where it enhanced phosphorylation of p65 serine-536
[17]. Since ERG occurs in a variety of isoforms and different fusion pro-
teins, an elucidation of its dissimilar biological functions in diverse cell
types requires a more detailed analysis of the differences in protein se-
quence and domain structure. Furthermore, it is important to note that
ERG-variants have the ability to form homo- or heterodimers generat-
ing an even higher functional diversity [18,19]. Since a complete under-
standing of the diverse functions of the various ERG isoforms is still
lacking, we set out to characterize the major protein isoforms in more
detail based on an elaborate analysis of differences in sequence and
functional domains and correlating biological functions.
2. Materials and methods
2.1. Cell culture and transfections
Primary human umbilical vein endothelial cells (HUVEC), lymphatic
endothelial cells (LEC) and SV40 immortalizedHUVECs (TERT-HUVECS)
were cultivated in M199 medium as described [20]. All other cell lines
(VCaP, HEK293, HeLa, KG-1 and EA.hy926) were maintained in DMEM
medium supplied with 10% FBS. Transient cell transfections were per-
formed with Turbofect™ (Thermoﬁsher, Germany) as recommended
by the manufacturer; HUVECs were transfected with polyethylenimine
as described in [21].
2.2. Gene expression and suppression constructs
cDNA from HUVEC and PCR were used to generate constructs for
ERG1, ERG3, ERG4 and ERG8 isoforms. The primers used to generate
these isoforms contained HindIII and SalI sites for cloning into the
pEGFP-C1 vector (Clontech, USA) resulting in EGFP–ERG1, EGFP–
ERG3, EGFP–ERG4 and EGFP–ERG8. The sequences of the primer sets
are described in Suppl. Table 1. PCR products were gel puriﬁed, digested
with HindIII and SalI and ligated into pEGFP-C1 digested with the same
enzymes. ERG1b was ampliﬁed by primers containing BglII and
EcoRV sites (Suppl. Table 1), inserted into the pGEM-T Easy vector
(Promega Inc. Madison, WI, USA.), cut out from the vector with
BglII and EcoRV and inserted into pARR2PB-Bluescript, a vector contain-
ing the prostate-speciﬁc, androgen dependent promoter ARR2PB,
obtained from R. Matusik [22]. EGFP–ERG1b was then obtained by
cutting out ERG1b from ARR2PB–ERG1b with Bgl II and Dra III and
ligating the insert into pEGFP–p65 [23], cut with the same enzymes,
thereby replacing p65 with Erg1b. All constructs were conﬁrmed by
sequencing before use. The nuclear localization sequence mutant
(EGFP–ERG1b–ΔRKSK) was generated by a deletion PCR reaction elim-
inating amino acids 337 to 340. For a mutation of the putative common
N-terminal nuclear export signal(s) the leucines at position 207 and
210 in ERG1b and ERG8 were mutated to arginine using appropriate
mutation primer sets. The second putative nuclear export sequence,
which is unique for ERG8, was mutated using appropriate mutation
primer sets (Suppl. Table 1). The PNT truncated ERG8 protein was gen-
erated by a deletion of the major part (amino acid 141 (W) to amino
acid AA 183 (F)) of the PNT domain using appropriate primers sets.
Two additional ERG mutants were generated, designated as W235R
and RRAA. W235R, harbors a single amino acid mutation close to the
DNA binding domain (replacing tryptophan-235 with arginine). For
the RRAA mutant two positively charged arginine residues of the core
DNA binding sequence of ERG (KLSRALR) as deﬁned by the crystalstructure of ERG bound to DNA [24] were mutated to alanines. These
two mutants were generated with the QuikChange mutagenesis kit
(Stratagene, Santa Clara, CA) using the mutation primers as speciﬁed
in Suppl. Table 1. A gene suppression construct targeting speciﬁcally
ERG8 was designed using the online siDesign Center of Dharmacon
(GE Life Sciences Inc) at http://dharmacon.gelifesciences.com/design-
center/ with the unique C-terminus of ERG8 as input. The candidate
with the highest score was selected and ordered as chemically synthe-
sized siRNA fromMicrosynth AG, Balgach, Switzerland with dTdT over-
hangs. A scrambled proven non-functional siRNA was used as control.
The sequences were as follows:
siERG8: sense: 5′-CUG UUG AUU UGG AGA CUA ATT, antisense: 5′-
UUA GUC UCC AAA UCA ACA G,
control-siRNA: sense: 5′-CGA GGA CUC UGA AUA GUG U, antisense:
5′-ACA CUA UUC AGA GUC CUC G.
2.3. Reporter gene assays
A luciferase reporter construct suited for determining the transcrip-
tional activity of ERG variantswas generated by inserting three copies of
the ERG consensus binding sequence into the vector pGL4.14 (from
Promega, USA). To that end, the following oligonucleotides were used:
Sense: 5′-CTAGCACAGGAAGATATCTACGGACAGGAAGCGATAAGCCTA
CAGGAAA-3′
Antisense: 3′-GTGTCCTTCTATAGATGCCTGTCCTTCGCTATTCGGATGT
CCTTTCTAG-5′
(sequences are shown as annealed double-stranded oligonucleotide
to emphasize the sticky ends ﬁtting to the restriction sites of the entry
vector; underlined: ERG-core binding region). These oligonucleotides
were annealed by mixing them at a concentration of 50 μg/μl followed
by incubation at 95 °C for 10 min in an Eppendorf thermomixer, and
slow cooling of the solution. The annealed oligonucleotideswere ligated
into a pGL4.14 vector cut with Bgl II and Nhe I. An improved luciferase
reporter construct for ERG activity (3× ERG-Nanoluc) was generated
with the same procedure by inserting the annealed double-stranded
oligonucleotide into a pNanoluc 1.1 vector (Promega Inc.). Luciferase re-
porter constructs were transfected in combination with a constitutively
expressing β-Galactosidase construct (driven by a ubiquitin-promoter:
pUB6/V5-His/lacZ from Life Technologies, Austria) or with a constitu-
tively expressing GFP-vector (pEGFP-C1, Clontech Inc. containing a
CMV-promoter) for normalization purposes together with ERG isoform
speciﬁc expression or gene suppression constructs. Cell extracts were
prepared and normalized luciferase activities were measured as de-
scribed in [23]. For measurements of ERG-dependent Nanoluc activity,
the substrate and protocol of the manufacturer (Promega Inc.) was
used.
2.4. Microscopy techniques
Confocal laser scanning microscopy was performed on Zeiss
LSM510 META and on Nikon A1 R+ equipment. FLIP (ﬂuorescence
loss in photobleaching) and FRAP (ﬂuorescence recovery after
photobleaching) were used to study the dynamics of ERG isoforms.
Cells were grown on 15 mm round glass cover slips (0.17 mm thick),
transfectedwith EGFP-tagged versions of proteins one day after seeding
and analyzed on the next day. Cover slips weremounted on a self-made
aluminum incubation chamber containing 80 μl medium and analyzed
as described in [25]. For detection and visualization of protein interac-
tions, we performed FRET (Fluorescence resonance energy transfer)
microscopy according to the 3-ﬁlter methodology as described in [26].
FRET microscopy was done with living cells expressing EGFP- and
mDsRed-tagged fusion proteins using a Zeiss LSM510 META system
and appropriate dichroic mirrors and ﬁlters sets. Monomeric DsRed
was detected with the spectral channel ChS1, GFP captured with chan-
nel 2 and the rawFRET signal acquired on channel 3 to obtainmaximum
sensitivity for FRET. For FLIP analysis of nucleo-cytoplasmic shuttling,
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and cells were observedwith a 40× oil immersion objective (numerical
aperture 1.3). Moderately ﬂuorescent cells were selected for analysis
and a circular region of interest was deﬁned in the cytoplasm. The cell
was imaged at low laser power (Ar-488 nm line, 6%) followed by 50
bleaching cycleswith high laser power (Ar-488 nm line, 100%) and sub-
sequent image acquisition of the whole cell as before. Approximately 5
cells were monitored and cytosolic as well as nuclear ﬂuorescence in-
tensities were quantiﬁed using ImageJ software. This analysis allows a
quantitative evaluation of the shuttling between nucleus and cytosol
[27]. In order to determine the mobility of ERG isoforms within the
nucleus, FRAP experiments were performed as described [28] using
a circular region of interest in the nucleus for bleaching. A Zeiss
LSM510 system was applied with a 40× oil immersion objective
and numerical aperture of 1.3. First a pre-bleaching image of a
whole cell was acquired at low laser power (6%) followed by 50–100
bleach cycles of the deﬁned region at high laser power (Ar-488 nm,
100%), and a subsequent time series of the bleached region of interest
at low laser power (Ar-488 nm, 6%). By scanning only the bleached re-
gion, a high time resolution could be obtained. After this series, a post-
bleaching image of thewhole cell was acquired to determine the overall
loss of ﬂuorescence. In the bleached area the recovery of the ﬂuores-
cence was calculated using ImageJ. The loss of ﬂuorescence from pre-
bleaching image to post-bleaching imagewas used to calculate a correc-
tion factor so that a correct recovery phase could be determined.
2.5. DNA binding assay (ABCD)
ABCD (Avidin Biotin Complex with DNA) assays were principally
performed as described [29,30]. In brief, HEK293 cells were transfected
with various ERG isoforms in 10 cm2 cell culture dishes. 24 h after trans-
fection cells were washed with PBS, centrifuged and resuspended in
1 ml of NTEN lysis buffer (10 mM Tris pH 8,0; 100 mM NaCl; 1 mM
EDTA pH 8,0; 10% glycerol; 0,5% Nonidet; 1 mM DTT), sonicated and
centrifuged. The pellet was discarded and 200 μl of cell lysates were in-
cubated with 2 μl of biotinylated oligonucleotides (50 μg/μl) containing
four ERG-consensus binding sites. Lysate/oligonucleotide mixtures
were then incubated with 40 μl streptavidin-conjugated agarose beads
(Novagen, USA), followed by 5× washing with 50 mM KCl at 4 °C, re-
moval of bound proteins with SDS-buffer by incubation for 5 min at
95 °C and separation by SDS-PAGE using 10% polyacrylamide gels.
Sequences of oligos used for ABCD assay were:
Sense: Biotin-5′-ACCGGAAGTGACCGGAAGTGACCGGAAGTGA
CCGGAAGT-3′ (binding sites are underlined).
Antisense: biotin— 5′ ACTTCCGGTCACTTCCGGTCACTTCCGGTCACTT
CCGGT 3′.
The same oligonucleotides without a biotin label were used as a
competitor control in 10-fold molar excess. Moreover, speciﬁcity of
the ABCD assay was assessed by using an ERG core-binding mutant
(RRAA, Fig. 6). Immuno-blotting was performed on PVDF-membranes
and ERG-isoforms were detected using antibodies (SantaCruz Biotech-
nology, USA, sc-353 X (ERG), or sc-8334 (GFP)) according to the
manufacturer's protocol. Of note, ERG8 was not detectable with an
ERG speciﬁc antibody, most likely because it is lacking the C-Terminus,
which contains the DNA-binding domain. Incubation of the lysates
with streptavidin beads in absence of any oligonucleotide served asneg-
ative control to test for unspeciﬁc binding to the beads. Cell lysates
themselves were applied to the gel as positive control to verify the
expression of the transcription factor.
2.6. Quantitative PCR analysis of ERG isoforms
We used isoform speciﬁc qPCR primers for the detection of each iso-
form in cell lines. The reaction was performed in a ﬁnal volume of 20 μl
using a SYBR green qPCR master mix (Thermoﬁsher, Germany). Nor-
malization was done using speciﬁc primers for GAPDH. The primersequences used are provided in Suppl. Table 2. The analysis was done
by using LinReg PCR software [31], which calculates the PCR efﬁciency
of each amplicon after determining the baseline ﬂuorescence. Relative
quantiﬁcation as compared to a control sample was calculated accord-
ing to [32]. Speciﬁc primers for ERG3 were not possible to design due
to thehomologieswith other isoforms. To address that,we used primers
that amplify all ERG isoforms (pan-ERG primers), calculated Cq values
for total ERG and subtracted the values of ERG1, 1b, -4, -7 and -8 to
get the value for ERG3 and all other potential isoforms. For Fig. 10, we
calculated the total amount of active ERGs by subtracting total ERG
fromERG8 expression relative toGAPDHandused these values to calcu-
late the ratio of active ERG/ERG8.
2.7. Statistics
Error bars represent S.E.M. if not stated differently. Numbers of rep-
licates (n-values) are speciﬁed in the ﬁgure legends. Unpaired t-tests
with two-tailed P-values were used for comparison of two groups.
One-way ANOVA with Dunnett's multiple comparison test was used
for Fig. 10. Statistical analysis was done with GraphPad Prism 5.0 or 6.0
software.
3. Results
3.1. Localization of ERG isoforms
Since antibodies discriminating between the ERG variants are not
available, we generated GFP-tagged fusion proteins of the isoforms
so as to localize them in living cells. Expression constructs were
transfected into HEK293 cells and 24 h after transfection, moderately
expressing cells were analyzed by confocal laser scanning microscopy.
ERG isoforms 1, 1b, 3 and 4 were predominantly found in the nucleus
with some weak ﬂuorescence in the cytosol, while ERG isoform 8 was
mainly localized to the cytoplasm (Fig. 1A). A quantiﬁcation of the dis-
tribution between nucleus and cytoplasm for a higher number of cells
conﬁrmed the notion that ERG8 differs signiﬁcantly from the other iso-
forms by localizing primarily in the cytoplasm (Fig. 1B).
3.2. Nuclear localization and nuclear export sequences of ERG isoforms
The result of themicroscopy of cells transfectedwithGFP-tagged ex-
pression constructs of the various ERG-isoforms prompted us to search
in more detail for potential nuclear localization sequences (NLS) and
nuclear export signals (NES) in the amino acid chains of the ERG-
variants. We identiﬁed a RKSK-sequence in the ETS domain as a poten-
tial nuclear localization sequence in ERG isoforms1, 1b, 3 and 4,which is
absent in ERG8 (Fig. 2A, marked in red). This putative NLS is in a region
that is very homologous for the different members of the ETS family.
The crystal structure of the ETS-1 protein, shows a conserved, ERG-
homologous sequence (RKNK) close to the helix that binds to the
major groove of the DNA (structure 2NNY, [33]). The very recent eluci-
dation of the DNA-bound structure of ERG itself [24] is in line with that
and presents the putative NLS close to the DNA-binding domain (struc-
ture 4IRI, Fig. 2B). ERG8 differs signiﬁcantly from all the other isoforms
by lacking the conserved ETS domain, which contains the nuclear local-
ization signal and theDNA-bindingdomain. Instead it holds a short, par-
ticularly distinct C-terminus. Based on the published information of
functional domains, the sequence analysis furthermore indicated that
isoforms 1 to 4 possess two transactivation domains whereas ERG8
contains only one of these.
In addition to nuclear localization signals, we also searched for po-
tential nuclear export signals in the amino acid sequences of the
major ERG isoforms as many transcription factors shuttle between nu-
cleus and cytosol. Nuclear export of proteins relies primarily on the
NES-receptor Crm1p and usually depends on a stretch of hydrophobic
residues, such as leucines or isoleucines separated by 1–4 amino acid
Fig. 1. Subcellular localization of ERG isoforms. (A) GFP tagged versions of ERG isoforms (EGFP–ERG1, –ERG1b, –ERG3, –ERG4, –ERG8) were transfected in HEK293 cells and nuclei were
stained with DAPI. Images of live cells were taken with a Nikon A1 R+ confocal microscope. (B) Box-Whiskers Plot of the nuclear to cytosolic ﬂuorescence ratio showing the 10–90 per-
centiles on a logarithmic scale (n ≥ 17).
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observed at the amino acid position 207 of all investigated ERGs. Inter-
estingly, ERG8 contains an additional potential NES, which is character-
ized by a stretch of leucines within its distinct C-terminus (Fig. 2A).
Toﬁrst test the functional role of the putative NLS of ERG isoforms 1–
4, we deleted the potential NLS in a GFP-tagged expression construct of
a representative isoform (ERG1b) and transfected the mutated plasmid
into HEK293 cells. As expected, the nuclear localization of this mutant
was considerably reduced as compared to the wild-type protein,
which was paralleled by an increase of cytoplasmic ﬂuorescence
(Fig. 3A). Quantiﬁcation of that effect for a higher number of cells re-
vealed a signiﬁcant decrease of the ratio of nuclear to cytoplasmicﬂuorescence in RKSK mutant cells as compared to cells transfected
with wild-type EGFP–ERG1b (Fig. 3B).
We next tested the functionality of the predicted nuclear export se-
quences. To that end, we ﬁrst mutated the leucines at position 207 and
210 of ERG8 to destroy the postulated common ﬁrst NES. The second
NES, which is speciﬁc for ERG8, was generated bymutating the leucines
at position 297 and 302. Mutation of the ﬁrst or second putative NES
both resulted in a reduction of ERG8 cytosolic localization and an in-
crease in nuclear ERG8 implying that both NES sequences are functional
in this isoform (Fig. 4A, B). Interestingly, we did observe that amutation
of the secondNES leads to a stronger reduction of the cytosolic to nucle-
ar localization of ERG8 as compared to a mutation of the ﬁrst NES
Fig. 2. Sequence comparison of the ERG isoforms used in this study. (A) Sequence alignment of ERG isoforms by VectorNTI-software: bold: ETS domain; bold and italics: postulated
transactivation domains; boxed and labeled with “PNT”: PNT domain; red, boxed and labeled with “NLS”: putative nuclear localization sequence (NLS); boxed and labeled with “NES”:
putative nuclear export sequences (NES); green, boxed and labeledwith “DBD”: DNA binding domain. Double-headed arrows indicate the fragment thatwas used for X-ray structure anal-
ysis shown in B. ERG1, ERG3, ERG4 and ERG8 are described in [3], ERG1b is the original ERG1 representing the ﬁrst reported ERG family member [42]. NCBI reference numbers and mo-
lecular weights of the proteins are indicated on the upper left side. (B) DNA bound structure of ERG (4IRI) showing the putative NLS in red and the DNA-binding helix in green (visualized
with Chimera 1.8 software).
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has a synergistic effect on the ERG8 protein localization. The cytosolic
to nuclear ratio was, however, not signiﬁcantly different in the double
NESmutant, as compared to the secondNESmutant alone (Fig. 4B), sug-
gesting that the second NES, which is speciﬁc for ERG8, has a stronger
effect than the ﬁrst NES, which is present in all the tested isoforms. Fur-
thermore we also tested whether a deletion of the PNT domain of ERG8
has an effect on its cytosolic localization.However,we could not observe
any signiﬁcant inﬂuence of this mutation on the subcellular distribution
of ERG8 (not shown).In order to test, whether the ﬁrst potential NES, which is present in
all the ERG isoforms, is functional as well, we mutated this region in
EGFP–ERG1b by replacing the ﬁrst two leucine residues. Since ERG1–4
are already predominantly nuclear at steady state, a further in-
crease in nuclear localization by mutating this NES is hardly visible
(Suppl. Fig. 1). To solve that issue, we applied a technique designat-
ed as ﬂuorescence loss in photobleaching (FLIP)microscopy, where one
compartment (the cytosol) is repetitively bleached by a strong laser,
followed by imaging of thewhole cell at low laser excitation. A decrease
of the ﬂuorescence intensity in a non-bleached compartment (such as
Fig. 3.Veriﬁcation of the putative nuclear localization sequence. (A) GFP-tagged-ERG1b and its NLSmutant (ERG1b-NLSmut.)were transfected into cells and assessed bymicroscopy. Cell
borders are outlined with a continuous line; nuclei are indicated by a dashed line. (B) Quantiﬁcation of cytosolic to nuclear ﬂuorescence intensity ratios for ERG1b and the ERG1b-NLS
mutant as indicated. (n = 12, p b 0.0001, error bars represent SEM).
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tween the two compartments. Such an approach can be exploited to
prove the functionality of a NES, as the nuclear ﬂuorescence of a shut-
tling protein decreases upon bleaching of the cytosol and this decrease
should be signiﬁcantly reduced bymutation of a functional NES. Apply-
ing this technique to ERG1b and ERG1b with a mutated putative NES
could clearly show that the postulated NES is functional, causing consti-
tutive nucleo-cytoplasmic shuttling in this ERG isoform (Fig. 4C, D and
Suppl. Fig. 2). FLIP experiments with the other major ERG isoforms
demonstrated that all of them shuttle between nucleus and cytosol
(Fig. 4E). This was also true for the mutants of the ﬁrst and the second
NES of ERG8, as well as the double NES mutant supporting the notion
that both NES are functional in ERG8 (Suppl. Fig. 3). This data also indi-
cates that there are other mechanisms controlling the ERG8 cytosolic
ratio. The fact that ERG8, which lacks a classical NLS is also present to
a minor extent in the nucleus and furthermore exhibits shuttling be-
tween nucleus and cytosol implies the presence of a non-classical, rath-
er weak NLS in this isoform.
3.3. Mobility of ERG isoforms in the nuclei of living cells
For further investigation of the dynamics of ERG isoforms another
microscopy technique termed FRAP (Fluorescence Recovery after
Photobleaching) was applied. This technique is suited to monitor the
mobility of a ﬂuorescent protein within a given compartment in living
cells. We performed this microscopy technique on HEK293 cells ex-
pressing EGFP-tagged ERG1, 1b, 3, 4 or 8 as described in the Methods
section. While ERG8 was predominantly expressed in the cytosol, a
smaller fraction was also visible in the nucleus. For reasons of compari-
son with the other isoforms, we therefore determined the mobility of
ERG8 in the nucleus as well. An area of interest in the nucleus was de-
ﬁned, scanned at low laser intensity, followed by bleaching at full laser
power and subsequent time-lapse imaging of the bleached area at low
laser excitation. The ﬂuorescence recovery in the region as a result of
diffusion of molecules from outside into the bleaching area was moni-
tored and quantiﬁed over time (Fig. 5). The resultingﬂuorescence inten-
sities over time could be ﬁtted with an exponential increase algorithm
resulting in the calculation of a plateau value and a half-life of recovery.
The ﬁrst parameter usually deﬁnes the percentage of generally mobile
molecules within that time window, and the second parameter is a
measure of the diffusion rate [28]. This analysis revealed clear differ-
ences between the ERG variants with ERG8 being the most mobile of
all tested isoforms. The overall mobility of ERG isoforms 1, 1b and 3
was almost the same as indicated by nearly identical ﬁtted plateau
values. The half-life of recovery appeared to be lower for ERG8 ascompared to ERG 1, 1b and 3, meaning ERG8 is more mobile as com-
pared to other isoforms (Fig. 5).
3.4. DNA-binding and transcriptional activities of ERG isoforms
Based on the sequence comparison shown in Fig. 2A, where ERG8
appeared to lack a functional DNA binding region within the ETS do-
main, we aimed at testing the DNA-binding capabilities of the ERG iso-
forms. To that end, we applied ABCD (Avidin-Biotin ComplexwithDNA)
assays as alternatives to radioactive EMSA's (electrophoretic mobility
shift assays). The isoform constructs were transfected into HEK293
cells and whole cell lysates were tested for their binding activities to
double-stranded biotinylated oligonucleotides containing the consen-
sus ERG-binding sequence. This assay revealed that ERG isoforms 1,
1b, 3 and 4 bind speciﬁcally to the ERG binding sites as expected. How-
ever, in the case of ERG8, the pull-down of the biotinylated oligonucle-
otide with streptavidin-beads did not show any signiﬁcant binding of
ERG8-protein (Fig. 6A, Fig. 9A, B). Furthermore, we included an ERG-
variant with a mutation in the DNA binding domain (replacing two ar-
ginines by alanines, termed RRAA-mutant) as a control, which also did
not show any signiﬁcant DNA binding. Combining this result with the
fact that ERG8 lacks theDNA-binding domain known from crystal struc-
ture analysis [24] led us to the conclusion that ERG8 is not speciﬁcally
binding to DNA and is therefore not acting as transcription factor. For
a further elucidation of the transcriptional activities of the major ERG
isoforms, we performed luciferase assays using a reporter construct
containing three consensus-binding sites for ERG. Transfection of cells
with this construct in combination with ERG1, 1b, 3, 4 or 8 showed
that ERG isoforms 1–4 acted as functional transcription factors, while
ERG8 did not show any signiﬁcant transcriptional activity (Fig. 6B).
Two non-functional variants of ERG (RRAA, W235) with mutations in
the DNA binding domain were again used as control. We conﬁrmed ex-
pression of the different isoforms in the samples used for luciferase as-
says on a Western blot (Fig. 6C). Since ERG8 protein is not detectable
with a normal ERG antibody, we also used a normal GFP antibody to
conﬁrm ERG8 protein expression (Fig. 6D).
3.5. ERG8 interacts with other ERG isoforms
It has been postulated that ERG-protein isoforms can form homo- or
heterodimers with other isoforms [36] or even other transcription fac-
tors such as Jun. [19]. To test for potential protein interactions between
the transcriptionally active ERG isoforms and ERG8,we transfectedGFP-
tagged ERG isoforms 1, 1b, 3 and 4 alongwithmDsRed-ERG8 inHEK293
cells and performed FRET (ﬂuorescence resonance energy transfer)
Fig. 4.Nuclear export sequences in ERG isoforms and nucleo-cytoplasmic shuttling. (A) EGFP–ERG8 andmutants of the twoputativeNES (NES1mut., NES2mut.), aswell as doublemutants
(NES1 + 2mut.), were transfected into HEK293 cells and analyzed by ﬂuorescence microscopy. (B) Quantiﬁcation of cytosolic to nuclear ﬂuorescence ratios of cells transfected as in (A).
n= 11, p b 0.0001. (C) Fluorescence loss in photobleaching (FLIP) analysis of EGFP-ERG1b and its nuclear export sequence mutant (EGFP-ERG1b-NESmut). HEK293 cells were seeded on
coverslips and transfected with GFP tagged versions of ERG1b or ERG1b with a mutated NES. A region of interest in the cytoplasmwas bleached with high laser power and ﬂuorescence
intensities were recorded as described in the Materials and methods section. A decrease of ﬂuorescence in the non-bleached compartment (the nucleus) indicates shuttling between nu-
cleus and cytoplasm (ﬂuorescence loss in photobleaching, FLIP). Nuclei of cells, in which the cytosol has been bleached, are indicated by arrows. Images before cytosol bleaching (Pre Cyt.
bleach) and after cytosol bleaching (Post Cyt. bleach) are shown. (D) Quantiﬁcation of the nuclear ﬂuorescence intensity in the course of repetitive cytosolic bleaching for ERG1b and the
ERG1b-NESmutant. One representative experiment out of six is shown. (E) FLIP analysis of the nucleo-cytosolic shuttling of the ERG isoforms 1, 1b, 3, and 8. A representative experiment is
shown (n = 4).
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teract with all the active isoforms and that this interaction occurred pri-
marily in the cytosol (Fig. 7). Despite the fact that we observed a
signiﬁcant FRET signal and thus a physical interaction between ERG8
and the other ERG-isoforms, we did not see a substantial shift of the lo-
calization of the active isoforms from the nucleus towards the cytosol.
Just the fraction of the ERGs that localized to the cytosol appeared to in-
teract with ERG8. Co-expressing two differentially tagged activeisoforms (ERG1 and ERG3) showed an interaction in the nucleus as
expected.
3.6. Effect of ERG8 expression on the transcriptional activity of the other
ERG isoforms
Since ERG8 could interactwith the other ERG isoforms andwas tran-
scriptionally inactive, we speculated that ERG8 could function as an
Fig. 5.Mobility of ERG isoforms in the nucleus. Evaluation of theﬂuorescence recovery after photobleaching (FRAP) to determine themobility in the nucleus. As for FLIP, HEK293 cellswere
seeded on coverslips and transfectedwith GFP tagged versions of ERG isoforms as indicated. Live cells were examinedwith a laser-scanningmicroscope. A region of interest in the nucleus
was bleachedwith high laser power and ﬂuorescence recovery in the same regionwas recorded. Themean of four experiments is shown. Non-linear regression analysis using a one-phase
association algorithm (least square ﬁt) was performed with the software GraphPad Prism 5.0™. The table below the graph shows the results of the analysis.
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cells with ERG1-4 alone or together with ERG8 and determined lucifer-
ase activity of an ERG dependent promoter. Using this approach, we
could detect a signiﬁcant reduction of the normalized ERG-dependent
luciferase activity for ERG1, 1b, 3 and 4 in the presence of ERG8
(Suppl. Fig. 4). However, when we determined ERG protein levels by
Western blot in these samples we could detect a reduction of ERG 1-4
protein levels in the ERG8 co-transfected samples (Suppl. Fig. 4). The re-
duced expression of active ERGs upon transfection with ERG8 might be
either an indirect transfection effect or an inﬂuence of ERG8 on the ex-
pression of the active ERG isoforms. In order to prevent an overexpres-
sion effect, we decided to test a potential functional role of ERG8 by a
speciﬁc knockdown in ERG-positive cells. To that end, we designed a
siRNA sequence that targets the unique C-terminus of ERG8. The speci-
ﬁcity of the ERG8 gene suppression was conﬁrmed by co-transfecting
ERG8-siRNA or a scrambled control-siRNA with GFP-tagged expression
constructs of ERG-isoforms (Suppl. Fig. 5). Transfecting endothelial cells
(HUVECs) with control- or ERG8-siRNA in combination with an ERG-
dependent improved luciferase construct (Nanoluc) revealed a signiﬁcant
increase in endogenous ERG-activity upon knockdown of ERG8 when
normalized to co-transfected GFP (Fig. 8A). Interestingly, the expression
of endogenous active ERG (primarily ERG3, as assessed by qPCR, Suppl.
Fig. 6) increased signiﬁcantly, when ERG8 expression was suppressed
(Fig. 8B). Nevertheless, normalizing ERG-dependent luciferase activity
to the ERG-protein band intensity still revealed a signiﬁcant upregula-
tion of ERG-dependent transcriptional activity after knockdown of
ERG8 (Fig. 8C) implying an inhibitory role of ERG8 in these cells.
3.7. ERG8 reduces DNA binding of ERG1b in vitro
As we found a higher ERG activity after gene suppression of ERG8,
we wanted to test, whether ERG8 interferes with DNA-binding of atranscriptionally active ERG isoform. To that end, we performed in
vitro DNA-binding assays with increasing amounts of ERG8 and con-
stant amounts of ERG1b. HEK293 cells were transfected either with
ERG1b or with ERG8 and cell extracts were mixed at different ratios
before adding biotinylated oligonucleotides with ERG-binding se-
quences and pull-down with streptavidin-beads, followed by Western
blot analysis of precipitated ERG-protein. Using this approach, we
detected a decrease of DNA-bound ERG1b with increasing levels of
ERG8 (Fig. 9A, C). However, this effectwas rathermild implying that ad-
ditional mechanisms account for the biological effect of ERG8.
3.8. The expression of active ERG isoforms versus ERG8 differs between
cancer and endothelial cells
Since there are no antibodies available that differentiate between
the distinct ERG isoforms on the protein level, we aimed to distinguish
between the isoforms on the mRNA level. To that end, we designed
primers that are speciﬁc for the different major isoforms based on the
published mRNA-sequences and analyzed their expression in various
endothelial and cancer cell lines. Quantitative PCR analyses indicated
that the isoforms 1–4 and 8 are differentially expressed in these cells
while isoforms 5 and 7 could not be detected in any of the cell lines test-
ed (Suppl. Fig. 6). Interestingly, our analyses revealed that there was a
difference in the ratio of active ERG's to ERG8 in the cells tested. We
quantiﬁed the ratio of active ERG's to ERG8 in primary endothelial
cells from veins (HUVECs), lymphatic vessels (LEC), SV40 immortalized
HUVECS (TERT-HUVECS), cancer-like endothelial hybridoma cells
(EA.hy 926, ATCC CRL-2922), the ERG-positive prostate cancer cell line
VCaP, in HeLa cells and the human acute myeloid leukemia cell line
KG-1. Interestingly, the active ERG to ERG8 ratio was signiﬁcantly
higher in endothelial cells as compared to all the three cancer cell
lines (Fig. 10). Furthermore, we could observe a reduction of the ERG
Fig. 6. DNA-binding and transcriptional activities of ERG isoforms. (A) DNA binding as assessed by ABCD assays (Avidin Biotin Complex with DNA). HEK293 cells were transfected with
various isoforms as indicated (ERG1, ERG1b, ERG3, ERG4, ERG8, RRAA-mutant) and the lysates subjected to ABCD assays using oligonucleotides with ERG-binding sites as described in
theMaterials andmethods section. Cell lysateswereused as positive control for expression of the ERG-isoform (lysate); a 10-foldmolar excess of a non-biotinylated oligonucleotide served
as competitor control (comp.) and cell lysates incubatedwith streptavidin-beads in the absence of any oligonucleotide as negative control (beads). The pull-down samples showbinding of
ERG isoforms to a biotinylated oligonucleotide containing known ERG binding sites (pull-down). (B) Reporter gene assay to determine the transcriptional activities of ERG-isoforms.
HEK293 cells were transfected with a luciferase reporter containing three ERG-binding sites (3× ERG-Luc) in combination with a constitutively expressing β-galactosidase construct
for normalization either in the absence of any ERG-isoform (GFP, control) or in presence of ERG-isoforms as indicated. In addition, known non-functional ERG variants with mutations
in the DNA-binding domain were tested (W235R- and RRAA-mutants as indicated and described in the Materials and methods section). Error bars represent standard deviation (n =
3). (C, D) Western blots using an ERG (C) or a GFP antibody (D) in samples used for luciferase assays.
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926, as compared to non-transformed endothelial cells. Statistical
analysis revealed no signiﬁcant difference between the three non-
transformed endothelial cell types and no difference within the cancer
cell lines, but a signiﬁcant difference between the cancer cell lines and
the benign cell types.
4. Discussion
ERG, a member of the ETS family of proteins, regulates the expres-
sion of many endothelial-speciﬁc genes like VE-Cadherin, ICAM-2,
VWF or VEGFR1 [37] and knockdown studies indicated that it is
involved in endothelial cell proliferation, migration and angiogenesis
[8] [38]. Apart from its physiological role in endothelial cells, ERG is
also aberrantly expressed either alone or as a fusion protein in a variety
of cancers. The genomic structure of the ERG gene indicates alternative
splicing, as well as several start codons and polyadenylation sites
resulting in a plethora of possible ERG isoforms, which might have dif-
ferent functions and account for differences of ERG-effects in distinct
cell types.We set out to investigate themajor ERG isoforms inmore de-
tail and to identify potential functional differences based on sequence
variations. Since no antibodies are available that would differentiate be-
tween the isoforms, we generated GFP-tagged expression constructs of
the major ERG isoforms ERG1, -1b, -3, -4 and -8 and monitored thelocalization of the chimeric proteins after transfection. Confocal laser
scanningmicroscopy of live cells revealed a predominant nuclear local-
ization for isoforms 1–4, as expected from other studies [13]. Some
moderate occurrence in the cytoplasm could also be observed for
these isoforms,whichhas also been reported previously [39]. In contrast
to that, ERG8 was primarily localizing to the cytosol. This ﬁnding was
corroborated by more detailed sequence analyses and alignment of
ERG-isoforms, suggesting the presence of a classical NLS in the ETS do-
main of ERG1–4, which is missing in ERG8. By mutating this putative
NLS in the GFP-expression constructs, we could verify the functionality
of this localization signal using live cell microscopy. Moreover, align-
ment of ERG8 with the other isoforms also indicated that the DNA-
binding domain is absent in ERG8. This DNA binding domain was re-
cently veriﬁed by X-ray structure analysis [24] and is located close to
the identiﬁed NLS of ERG1-4. This is in line with our DNA-binding stud-
ies, which revealed that the isoforms 1 to 4 bound speciﬁcally to an ERG
consensus-binding site, while ERG8 did not show any signiﬁcant
binding.
Based on the speciﬁc localization of ERG8 in the cytosol we applied
further sequence analyses searching for potential nuclear export se-
quences (NES). These localization signals are usually characterized by
a stretch of four hydrophobic residues, typically leucines or isoleucines,
separated by short spacers of 1 to 4 amino acids [40]. This structure is
more difﬁcult to recognize as compared to NLS. Nevertheless, we
Fig. 7. ERG8 interactswith other ERG isoforms. Representative FRETmicroscopy analysis of ERG isoforms 1 to 4 binding to ERG8. Cellswere transfectedwith ERG-isoforms taggedwith GFP
or mDsRed (red) as indicated and subjected to 3-Filter FRET microscopy as described in the Materials and methods section. A corrected FRET image according to [43] was calculated
(FRETcorr), as well as an image showing the apparent FRET efﬁciency (app. E) as described in [44]. An example of the interaction between two active isoforms is shown at the last row
(ERG1/ERG3). The last two columns (FRET corr and app. E) are shown in a pseudocolor mode to visualize low values.
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forms. In addition, we identiﬁed a potential NES in the unique C-
terminus of ERG8. The presence of nuclear import as well as export sig-
nals in the ERG isoforms could be substantiated by live cell microscopyusing a technique named ﬂuorescence loss in photobleaching (FLIP),
which monitors the dynamic exchange of ﬂuorescently tagged mole-
cules between two compartments. Repetitive bleaching of a cytosol-
restricted region resulted in a decrease of nuclear ﬂuorescence for all
Fig. 8. Effect of ERG8 knockdown on the transcriptional activity of endogenous ERG isoforms in endothelial cells. HUVECs were transfected with scrambled control si-RNA (si-control) or
siRNA targeting the unique C-terminus of ERG8 (siERG8) in combination with an improved ERG-dependent luciferase reporter construct (ERG-Nanoluc) and a constitutively expressing
GFP-reporter for normalization. (A) ERG-luciferase activity in cell extracts normalized to GFP ﬂuorescence. (B) Western blot analysis of the extracts shown in (A) with an anti-ERG anti-
body (upper panel), recognizing endogenous ERG1-4 but not ERG8, which lacks the epitope, aswell aswith GAPDH antibodies (lower panel) as loading control. (C) ERG luciferase activity
of the extracts, when normalized to the ERG-protein band shown in (B). n = 3, error bars represent SEM; an asterisk indicates statistical signiﬁcance with an unpaired students t-test.
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was even true for ERG8, which does not contain a classical NLS, but
which exhibits also some weak nuclear localization. Given the fact
that GFP-conjugated ERG8 is most likely above the threshold for unspe-
ciﬁc diffusion through thenuclear pore complex,which is in the range of
30–40 kDA,we suppose the presence of a ratherweak, non-classical nu-
clear import mechanism for ERG8. In addition to the dynamic exchange
of ERGmolecules between nucleus and cytosol, we also tested theirmo-
bilitywithin a given compartment. Sincemost of the ERG isoforms local-
ized primarily to the nucleus, we investigated their diffusion kinetics
within this compartment using the FRAP (ﬂuorescence recovery after
photobleaching) technique. All the transcriptionally active and DNA-
binding isoforms showed a similarmobility in this assay reaching a pla-
teau at about 45% of the initial ﬂuorescence, which implies that about
55% of the molecules are immobile within the time frame of the exper-
iments for instance due to binding to DNA. The mobile fraction showedFig. 9. Effect of ERG8 on the DNA binding activity of ERG1b. (A) Lysates of cells transfected
with either ERG1b or ERG8 were mixed at different ratios (1:0, 0:1, 1:1, 1:2, 1:3, 1:4, 1:5)
and subjected to an ABCD DNA-binding assay with biotinylated oligonucleotides contain-
ing ERG-binding sites. After pull-down with streptavidin-beads, bound ERG molecules
were detected by SDS-PAGE and Western blots. (B) Quantiﬁcation of Western blots as
shown in (A). ERG1bDNA-binding capability decreasedwith increasing amounts of ERG8.similar diffusion kinetics as assessed by the half time of ﬂuorescence re-
covery. Again, ERG8 differed from the other ERG-isoforms. It appeared
more mobile, reaching a plateau at about 62% of the initial ﬂuorescence
and showed a faster half time of ﬂuorescence recovery. This is in line
with the notion that it does not bind to DNA as suggested by our in
vitro DNA-binding assays — and consistent with the X-ray structure
analysis.Fig. 10.Ratio of total active ERG-isoformmRNA to ERG8-mRNA.mRNAwas extracted from
the different cell types indicated, reverse transcribed and subjected to quantitative PCR as
described in the Materials and methods section (n= 3, error bars represent standard de-
viations). One-wayANOVA andDunnett'smultiple comparison testswere performedwith
GraphPad Prism software. Signiﬁcance of difference is indicated (n.s.: non-signiﬁcance ap-
plies to comparison betweenHUVECSwith TERT-HUVECS and LEC cells; p b 0.0001 applies
to comparisons between HUVECs with EaHy, VCAP, HeLa, and KG-1 cells).
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porter gene assays using ERG-dependent luciferase constructs. ERG 1–4
exhibited a clear transcriptional activity, while ERG8 did not lead to any
signiﬁcant luciferase signal similar to DNA bindingmutants of an active
ERG variant.
The fact that ERG8 appeared transcriptionally inactive in reporter
gene assays and did not bind to ERG speciﬁc oligonucleotides implies
that it is not a functional transcription factor. However, we found that
it can interact physically with the other major ERG variants as assessed
by FRET microscopy, which is in line with the view that ERG molecules
can formhomo- andheterodimers [36]. Since ERG8 did not bind to DNA,
was transcriptionally inactive and localized to the cytosol, we suspected
that it might act as an inhibitor of the other ERG isoforms. Indeed, we
found a signiﬁcant increase of endogenous ERG activity in luciferase as-
says after knockdown of ERG8. Interestingly, suppression of ERG8 levels
by siRNA resulted in a concomitant increase in the level of active ERG in
primary endothelial cells suggesting a negative feedback mechanism
between expression of ERG8 and the transcriptionally active isoforms.
However, even after normalization to the amount of active ERG, an in-
hibitory effect of ERG8 on overall ERG-dependent transcriptional activ-
ity could be observed.
This inhibitory activity of ERG8 might be caused by different mech-
anisms: Given that ERG8 shows physical interaction with the other iso-
forms, it might drag these out of the nucleus towards its own
predominant localization in the cytosol. However, analysis of the local-
ization after co-transfection of ERG8 with other isoforms indicates that
only part of the molecules are interacting with each other at steady
state — and that this does not change the predominant localization of
the molecules. Therefore, we assume that other, or at least additional
mechanisms account for an inhibitory effect of ERG8. One possibility is
that ERG8 might inhibit binding of active ERG isoforms to DNA. Testing
this hypothesis by analyzing theDNA-binding activity of ERG1bwith in-
creasing amounts of ERG8 revealed a rather moderate but clear reduc-
tion of ERG1b-binding to DNA (Fig. 9). However, the magnitude of this
effect was rather low and was not observed for a second isoform that
we tested (ERG3). Therefore, we propose that further mechanisms
such as a reduced transcriptional activity of ERG dimers containing
ERG8 account for its inhibitory activity. Indeed, ERG8 contains only
one consensus transactivation domain,while the other isoforms contain
two (Fig. 2), supporting the notion that ERG8-containing dimers would
have a lower activity in recruiting the transcriptional machinery. Fur-
thermore, ERG8 might have additional functions in the cytosol. It has
been shown previously, that ERG molecules can interact with Jun. and
Fos [41], both of which can localize to the cytosol at signiﬁcant levels.
Thus, ERG8 might also interact with these transcription factors and
have speciﬁc biological roles beyond those of other ERG isoforms.
An important conclusion of our study is that ERG is actually not a sin-
glewell-deﬁned transcription factor, but rather a family of proteins aris-
ing from alternative splicing, different start codons and polyadenylation
sites resulting in a diversity of protein variants. One of the isoforms that
we tested, ERG8, turned out to be an inactivemember of this family and
to exert inhibitory functions on the other isoforms. Its biological role canFig. 11. Summary of ERG isoforms illustrating the identiﬁed NES and NLbe explained at least in part by the lack of a classical nuclear localization
sequence, a missing DNA-binding domain and the presence of an addi-
tional nuclear export sequence in its unique C-terminus as illustrated in
Fig. 11.
Since different or even contrary biological functions of ERG, such as
pro-inﬂammatory roles in prostate cancer cells [17] as opposed to
anti-inﬂammatory functions in endothelial cells [12,13] might be
caused by differential expression of ERG isoforms, we established quan-
titative PCR analysis to distinguish the major variants in different cell
types. This analysis revealed distinct proﬁles of isoform expression,
which by themselves where not yet conclusive. However, calculating a
ratio of transcriptionally active ERG-isoforms and ERG8 revealed an in-
teresting general difference between non-cancer cells and four different
cancer cell lines tested. In general, endothelial cells showed a higher de-
gree of active ERGs to ERG8 as compared to the cancer cell lines. Fur-
thermore, we observed a signiﬁcant reduction of the active ERG to
ERG8 ratio in the endothelial hybridoma cell line EA.hy926. This cell
line was generated by fusion of HUVECs with the lung cancer cell line
A549 and retains most of the characteristics of an endothelial cell line.
Based on our ﬁndings, it is thus tempting to speculate that a higher ex-
pression of ERG8 in cancer cells could inhibit other ERG isoforms, which
might result in a general imbalance of the transcriptional activity of the
ERG isoforms expressed. This imbalance could for example, contribute
to a proliferative and less apoptotic phenotype of the cancer cells. Our
results also imply that a preponderance of active ERGs might rather
drive differentiation than transformation of cells. However, further
studies are needed to extend this observation - and to study whether
the individual active ERG-isoforms exhibit distinct biological roles for
instance by driving diverse sets of target genes. Furthermore, we cannot
exclude the possibility that other potentially expressed ERG isoforms,
which are maybe even ampliﬁed by the same PCR-primers that we
used in this study, are contributing to the observed differences in ex-
pression patterns and are exerting differential effects. Distinct functions
of ERG transcription factors in different cell types might not only be
caused by a differential expression of ERG-isoforms, but also by differ-
ences in the genomic accessibility for these transcription factors.We as-
sume that this contributes strongly to the observed differences in
biological roles of ERGs in various cell types. An analysis of microarray
data on ERG-induced genes in endothelial cells as compared to prostate
cancer cells revealed a very small overlap of just about 3% of the ERG-
regulated genes (see Supplementary Information). We speculate that
this striking difference in the set of target genes cannot be explained
simply by different ratios of active ERGs versus ERG8 or differential ex-
pression of the individual active isoforms, but at least in addition by dis-
tinctive responsiveness of the cell types to ERGs.
Nevertheless, it would be intriguing to investigate a potential differ-
ential expression of ERG8 in a variety of cell types or diseases usingmi-
croarray analyses, e.g. by re-analyzing publicly accessible databases.
However, the fact that ERG8 differs from the other isoforms only in a
rather short C-terminal region, hinders microarray analyses due to the
lack of ERG8-speciﬁc probe sets on common microarray platforms.
Therefore, we suspect that quantiﬁcation of ERG8 by means of exomeS domains in combination with the known PNT and ETS domains.
217B. Hoesel et al. / Biochimica et Biophysica Acta 1863 (2016) 205–218sequencing or proteomics might be valuable in the future to clarify
whether it is correlatedwith cell types or disease states. In addition,mi-
croarray or RNA-sequencing analyses after speciﬁc knockdown of ERG8
in endothelial and cancer cells might address the biological function of
ERG8 in more detail.
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